Berry Genomics (China) Today
| 000710 Stock | 8.19 0.16 1.92% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Berry Genomics is trading at 8.19 as of the 2nd of February 2025, a 1.92 percent decrease since the beginning of the trading day. The stock's open price was 8.35. Berry Genomics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 3rd of January 2025 and ending today, the 2nd of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of April 1997 | Category Healthcare | Classification Health Care |
Berry Genomics is entity of China. It is traded as Stock on SHE exchange. The company has 353.52 M outstanding shares. More on Berry Genomics Co
Moving against Berry Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Berry Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Berry Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Berry Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| GM Chairman | Yang Gao | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Berry Genomics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Berry Genomics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsBerry Genomics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Berry Genomics' financial leverage. It provides some insight into what part of Berry Genomics' total assets is financed by creditors.
| |||||
Berry Genomics Co (000710) is traded on Shenzhen Stock Exchange in China and employs 1,448 people. Berry Genomics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.36 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Berry Genomics's market, we take the total number of its shares issued and multiply it by Berry Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Berry Genomics operates under Biotechnology sector and is part of Health Care industry. The entity has 353.52 M outstanding shares.
Berry Genomics generates positive cash flow from operations, but has no cash available
Check Berry Genomics Probability Of Bankruptcy
Ownership AllocationBerry Genomics holds a total of 353.52 Million outstanding shares. Berry Genomics Co retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Berry Ownership Details
Berry Genomics Risk Profiles
Although Berry Genomics' alpha and beta are two of the key measurements used to evaluate Berry Genomics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.42 | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.23 | |||
| Risk Adjusted Performance | (0.02) |
Berry Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Berry Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Berry Genomics Corporate Executives
Elected by the shareholders, the Berry Genomics' board of directors comprises two types of representatives: Berry Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Berry. The board's role is to monitor Berry Genomics' management team and ensure that shareholders' interests are well served. Berry Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Berry Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daixing Zhou | CoFounder Scientist | Profile | |
| Dong Wang | Deputy CFO | Profile |
Other Information on Investing in Berry Stock
Berry Genomics financial ratios help investors to determine whether Berry Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Berry with respect to the benefits of owning Berry Genomics security.